DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for enterobiasis — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEnterobiasis maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for enterobiasis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
BicC family RNA binding protein 1 (BICC1) — BICC1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet xpedrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6GY4 · 1.986 Å · ligand 3,6,9,12,15,18,21,24,27-NONAOXANONACOSANE-1,29-DIOL (XPE). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
ABDIKAN Jurnal Pengabdian Masyarakat Bidang Sains dan Teknologi · 2024 · 0 citations · open access
Penatalaksanaan Enterobiosis pada Anak Melalui Pendekatan Kedokteran Keluarga
AbstractEnterobiosis in children remains a serious public health problem in many developing countries, including Indonesia. The epidemiology of Enterobiasis disease shows a high prevalence especially in areas with poor sanitation and limited access to health services. The pathophysiology of Enterobiasis disease involves infection with parasitic worms such as Enterobius vermicularis which can cause various health complications in children, including anemia, impaired growth, and impaired cognitive development. Service activities carried out by providing advice/support to Enterobiosis patients are considered through self-history, home visits by adopting a holistic and comprehensive family medicine approach. The aim of patient counseling/support is to increase awareness of the disease and improve the quality of life of the patient. The results of service activities and home visits show that patients have a better understanding of their disease and the level of compliance with treatment and healthy living behavior, which affects the success of treatment. Comprehensive treatment with a family medicine approach is needed to identify problems in various ways, support the success of therapy, and improve the quality of life of patients.
Infectious diseases · 2024 · 0 citations · open access
Burden of Enterobiasis in Africa: Overcoming Neglect and Improving Pediatric Health
AbstractEnterobiasis is a globally prevalent, difficult-to-control, but yet neglected intestinal helminthiasis. Its asymptomatic nature in most cases leads to underestimation of its impact. However, its impact on pediatric health is significant, compromising their physical and mental well-being ultimately hampering educational development. The prevalence of enterobiasis among (pre)school-aged children in Africa varies across studies due to differences in study location characteristics and diagnostic techniques. However, higher prevalences have been reported in studies utilizing the scotch tape technique emphasizing the need for its prioritization in epidemiological studies and routine parasitological examinations due to its high diagnostic efficiency. Mebendazole (100 mg orally) is the recommended first-line treatment, and administering a second dose after 14 days is crucial to prevent reinfection. The scarcity of treatment data for enterobiasis in Africa can be attributed to various factors, including underreporting of cases, limited healthcare infrastructure, and inadequate research focus on this specific parasitic infection. Overcoming the neglect of enterobiasis requires the implementation of educational and mass treatment programs, improving diagnostic capabilities, and prioritizing research and public health initiatives. Additionally, improving hygiene practices and sanitation is essential. By addressing these challenges and introducing comprehensive interventions, the neglect of enterobiasis can be overcome, leading to improved overall African pediatric well-being.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
